Fernandoa
adenophylla (Wall. ex
G. Don) Steenis is traditionally used to cure various diseases and
can be included as an ingredient in massage oils, which are supposed
to comfort muscular tension and pain. This study was designed to assess
the antinociceptive, muscle relaxant, and molecular docking properties
of a novel compound, namely, (5aR,5a1R,6R,7aS,14bR,15R)15-hydroxy-7a-methyl-6-(2-methylprop-1-en-1-yl)-7,7a,14b,15-tetrahydro-5H-t-5a,15methanobenzo[g]benzo[5,6]azuleno[1,8-bc]chromene-5,9,14,16(5a1H,6H)- tetraone
(peshawaraquinone), isolated from the methanolic extract of F. adenophylla in an animal model. The chemical structure
of the isolated compound was elucidated using advanced spectroscopic
techniques and further confirmed by XRD analysis. Compound 1 was tested against hot plate-induced noxious stimuli at various
doses (2.5, 5, 10, and 15 mg/kg i.p.). The muscle relaxation potency
of compound 1 was evaluated in the inclined and traction
test, while the open-field test was used for the determination of
sedative potential. The isolated compound was also subjected to acute
toxicity analysis. The compound was then subjected to molecular docking
analysis to determine the exact mechanism of action. Compound 1 demonstrated significant (p < 0.05)
analgesic effect in a dose-dependent manner. A noticeable muscle relaxant
effect was observed with the passage of time in both experimental
models. The compound 1 showed a significant (p < 0.05) sedative effect, and in an acute toxicity study,
the compound 1 was devoid of any noxious effects. The
docking studies showed preferential affinity for μ-opioid and
GABAA receptors. Hence, the prospective antinociceptive and muscle
relaxant and sedative properties are probably mediated through these
two target interactions.